TG Therapeutics (NASDAQ:TGTX) Q1 2026 Earnings Beat Revenue Guidance but Miss EPS Estimates
TG Therapeutics (NASDAQ:TGTX) Q1 2026 Earnings Beat Revenue Guidance but Miss EPS Estimates ChartMill
Covered in this story
Call it yourself
No calls on $TGTX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Tg Therapeutics Inc →Summary aggregated from ChartMill's public RSS feed. The full reporting belongs to ChartMill — please read it on their site.